GRK2 and heart failure: With NE levels corresponding to the elevated baseline used to simulate early heart failure, the joint treatment of β-blockers with GRK2 downregulation reduces the overshoot amplitude (1.18 μM cAMP) for a fixed dynamic range of 0.26 μM cAMP.